Advanced Filters
noise

rheumatoid-arthritis Clinical Trials

A listing of rheumatoid-arthritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 267 clinical trials

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can …

18 - 80 years of age All Phase 2
G Giovanni Adami, MD

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Purpose The study aims to investigate how Filgotinib affects proteins and micro-RNA in the blood of patients with rheumatoid arthritis. This could help understand its impact on inflammation and bone health in these patients. Study Design: This is a single-center, prospective randomized study.

18 - 65 years of age All Phase 4
A Audrey JANOLY-DUMENIL, PharmD

RhEumatoid Arthritis MEDIcation Adherence

Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health …

18 years of age All Phase N/A
M Marie Hudson, MD MPH

Stand UP to Rheumatoid Arthritis (SUPRA)

Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is …

18 years of age All Phase N/A

Cilostazol and Methotrexate in Rheumatoid Arthritis

This study aims at evaluating the therapeutic effects of Cilostazol as adjuvant therapies to low dose of Methotrexate in patients with Rheumatoid Arthritis and to evaluate their impact on Cyclic adenosine monophosphate(CAMP), Heme Oxygenase-1(HO-1).

18 - 60 years of age All Phase 3
S Stacey Boetto, DNP, FNP-C

Probiotics in Adults With Rheumatoid Arthritis

The goal of this clinical study is to collect data on the effect of probiotic administration on clinical outcomes in rheumatoid arthritis patients. Participants will: Have a 6-week daily administration of a probiotic Collect fecal samples every other day during the first 3 weeks of the study and twice weekly …

18 years of age All Phase N/A

Fexofenadine in Patients With Active Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying …

18 - 60 years of age All Phase 1/2
A Al-Azhar Universiy

Pulse Steroid Injection in Refractory Rheumatoid Arthritis

Remission or low disease activity in active rheumatoid arthritis

20 - 65 years of age All Phase 3

L-carnitine Supplementation in Rheumatoid Arthritis Patients

This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.

18 - 60 years of age All Phase 2
M Mostafa M Bahaa, PhD

Paroxetine Safety and Efficacy in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic chronic auto-inflammatory disorder which imposes a remarkable burden of morbidity and mortality on global health. The complex interaction between genetics, environment, and immunological response contribute to RA pathogenesis. Current treatment comprises conventional disease-modifying anti-rheumatic drugs (DMARDs) followed by biological DMARDs, if necessary, to achieve …

23 - 57 years of age All Phase 3

Simplify language using AI